{"id":22821,"date":"2017-07-04T10:23:53","date_gmt":"2017-07-04T10:23:53","guid":{"rendered":"https:\/\/corporate.webfactory.ferring.tech\/?p=22821"},"modified":"2021-05-10T18:08:09","modified_gmt":"2021-05-10T17:08:09","slug":"ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients","status":"publish","type":"post","link":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/","title":{"rendered":"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients"},"content":{"rendered":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h2 style=\"color: #0088ce\">Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients<\/h2>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<ul>\n<li>New analysis of Rekovelle\u00ae data presented at ESHRE showed similar cumulative live birth rates compared to conventional therapy<\/li>\n<\/ul>\n<ul>\n<li>New analysis of Rekovelle data also presented on safety profile in women undergoing IVF, including those with high AMH levels<\/li>\n<\/ul>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">Saint-Prex, Switzerland \u2013 4 July, 2017<\/h3>\n<p class=\"p1\">Ferring Pharmaceuticals announced today a new analysis of Rekovelle<span class=\"s1\">\u00ae<\/span>\u00a0(follitropin delta) data that showed cumulative live birth rates were similar between women receiving Rekovelle and conventional follitropin alfa treatment.<a href=\"#note1\"><sup>1<\/sup><\/a> In addition, Rekovelle data from a separate new analysis showed a favourable safety profile in women with high anti-M\u00fcllerian hormone (AMH) levels.<sup><a href=\"#note2\">2<\/a><\/sup> These analyses of the ESTHER-1 and ESTHER-2 Phase III clinical trials<sup><a href=\"#note3\">3<\/a>,<a href=\"#note4\">4<\/a><\/sup>\u00a0were presented today at the 33<span class=\"s1\">rd<\/span>\u00a0Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Geneva, Switzerland.<\/p>\n<p class=\"p1\">\u00a0\u201cRekovelle\u2019s individualised dosing regimen, based on a patient\u2019s AMH level and body weight, provides clinicians with a consistent, evidence-based approach to personalising treatment for their patients,\u201d said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals. \u201cThese new Rekovelle analyses add further evidence for a personalised approach to fertility treatment for patients.\u201d<\/p>\n<p class=\"p1\">A new analysis of the ESTHER-1 and ESTHER-2 trials showed that in women undergoing in vitro fertilisation (IVF), the cumulative live birth rate for fresh embryo transfers after three treatment cycles was 43.9% (292\/665) with Rekovelle and 44.5% (294\/661) with follitropin alfa.<a href=\"#note1\"><sup>1<\/sup><\/a>\u00a0In addition, ongoing pregnancy rate was 45.1% (300\/665) and 45.7% (302\/661), respectively.<a href=\"#note1\"><sup>1<\/sup><\/a> The ESTHER trials<sup><a href=\"#note3\">3<\/a>,<a href=\"#note4\">4<\/a><\/sup>were not powered for this analysis, so no confirmatory conclusions can be derived.<\/p>\n<p class=\"p1\">A separate new analysis of the ESTHER-1 trial was conducted to evaluate ongoing pregnancy rates, early ovarian hyperstimulation syndrome (OHSS) and preventive interventions for early OHSS in women with different AMH levels.<sup><a href=\"#note2\">2<\/a><\/sup>\u00a0For women with high AMH \u226535 pmol\/L (13% of the trial population) the incidence of early OHSS with Rekovelle was lower (4.7%, 4\/86) compared with conventional follitropin alfa dosing (11.9%, 10\/84). The number of patients requiring preventive interventions for early OHSS was also lower (4.7%, 4\/86 and 23.8%, 20\/84 respectively). In addition, patients maintained ongoing pregnancy rate.<sup><a href=\"#note2\">2<\/a><\/sup> The ESTHER trials<sup><a href=\"#note3\">3<\/a>,<a href=\"#note4\">4<\/a><\/sup>\u00a0were not powered for this analysis, so no confirmatory conclusions can be derived.<\/p>\n<p>&#8211; ENDS &#8211;<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">About Rekovelle<sup>\u00ae<\/sup>\u00a0(follitropin delta)<\/h3>\n<p class=\"p1\">Rekovelle is the first recombinant follicle stimulating hormone (rFSH) derived from a human cell line (PER.C6<span class=\"s1\">\u00ae<\/span> cell line).<sup><a href=\"#note3\">3<\/a>,<a href=\"#note5\">5<\/a>,<a href=\"#note6\">6<\/a>,<a href=\"#note7\">7<\/a><\/sup>\u00a0It has been developed for individualised dosing based on a patient\u2019s body weight and serum AMH level, as determined by a companion diagnostic, the Elecsys<span class=\"s1\">\u00ae<\/span> AMH Plus immunoassay from Roche.<sup><a href=\"#note3\">3<\/a>,<a href=\"#note8\">8<\/a>,<a href=\"#note9\">9<\/a><\/sup>\u00a0Rekovelle is structurally and biochemically distinct from other existing recombinant FSH treatments.<sup><a href=\"#note3\">3<\/a>,<a href=\"#note5\">5<\/a>,<a href=\"#note6\">6<\/a>,<a href=\"#note7\">7<\/a><\/sup><\/p>\n<p class=\"p1\">Rekovelle<span class=\"s1\">\u00ae<\/span>\u00a0received Marketing Authorisation from the European Commission (EC) in December 2016.<\/p>\n<h3 style=\"color: #0088ce\">About the ESTHER trials<\/h3>\n<p class=\"p1\"><span class=\"s1\">ESTHER-1 (<b>E<\/b>vidence-based\u00a0<b>S<\/b>timulation\u00a0<b>T<\/b>rial with\u00a0<b>H<\/b>uman recombinant FSH in\u00a0<b>E<\/b>urope and\u00a0<b>R<\/b>est of World)\u00a0is a Phase 3, randomised, assessor-blind, controlled trial of 1326 patients in 11 countries undergoing their first ART cycle. Patients were randomized 1:1 to receive treatment with individualised Rekovelle, a fixed daily dose based on serum anti-M\u00fcllerian hormone (AMH) levels and body weight, or conventional follitropin alfa dosing. The co-primary endpoints of ongoing pregnancy rates and ongoing implantation rates were met and results showed no difference between the two treatment arms.\u00a0Results of the ESTHER-1 trial were published in the February 2017 issue of\u00a0<i>Fertility &amp; Sterility<\/i>.<a href=\"#note3\"><span class=\"s2\"><sup>3<\/sup><\/span><\/a><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">ESTHER-2 is a Phase 3, assessor-blind, controlled trial evaluating the immunogenicity of Rekovelle in a subset of ESTHER-1 patients undergoing repeated cycles of controlled ovarian stimulation for ART. Data demonstrated no increased immunogenicity risk with Rekovelle after exposure in repeated cycles.<a href=\"#note4\"><span class=\"s2\"><sup>4<\/sup><\/span><\/a><\/span><\/p>\n<h3 style=\"color: #0088ce\">About AMH and OHSS<\/h3>\n<p class=\"p1\"><span class=\"s1\">AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response.<a href=\"#note10\"><span class=\"s2\"><sup>10<\/sup><\/span><\/a>\u00a0Women with high AMH levels are at an increased risk of developing OHSS, a potential complication of IVF treatment.<a href=\"#note11\"><span class=\"s2\"><sup>11<\/sup><\/span><\/a><\/span><span class=\"s3\"><sup>,<\/sup><a href=\"#note12\"><span class=\"s4\"><sup>12<\/sup><\/span><\/a><\/span><span class=\"s1\">\u00a0Symptoms of early OHSS may include abdominal distension or discomfort, nausea and vomiting. In more severe cases OHSS can lead to large amounts of ascites (fluid accumulation in the abdominal cavity), shortness of breath, blood clots, dehydration and potentially, death.<a href=\"#note11\"><span class=\"s2\"><sup>11<\/sup><\/span><\/a>\u00a0<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">The prevalence of OHSS in women undergoing IVF varies according to severity, with cases of OHSS experienced by 20\u201333% (mild), 3\u20136% (moderate) and 0.1\u20132% (severe) of women.<a href=\"#note13\"><span class=\"s2\"><sup>13<\/sup><\/span><\/a>\u00a0A recent report suggested that OHSS is an underreported side effect of ovarian stimulation and the real world incidence may be higher.<a href=\"#note14\"><span class=\"s2\"><sup>14<\/sup><\/span><\/a>\u00a0In addition to the impact on patients, the treatment of OHSS is associated with significant costs to the healthcare system.<a href=\"#note15\"><span class=\"s2\"><sup>15<\/sup><\/span><\/a>\u00a0In the UK for example, the cost of treating moderate and severe cases of OHSS is estimated to be over \u00a37 million every year.<a href=\"#note15\"><span class=\"s2\"><sup>15<\/sup><\/span><\/a><\/span><span class=\"s3\"><sup>,<\/sup><a href=\"#note16\"><span class=\"s4\"><sup>16<\/sup><\/span><\/a><\/span><\/p>\n<h3 style=\"color: #0088ce\">About Ferring Pharmaceuticals<\/h3>\n<p>Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company\u2019s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit\u00a0<a href=\"https:\/\/www.ferring.com\/\">www.ferring.com<\/a>.<\/p>\n<h3 style=\"color: #0088ce\">About the Elecsys<sup>\u00ae<\/sup>\u00a0AMH Plus immunoassay from Roche<\/h3>\n<p class=\"p1\"><span class=\"s1\">The Elecsys<\/span><span class=\"s2\"><sup>\u00ae<\/sup><\/span><span class=\"s1\">\u00a0AMH Plus immunoassay from Roche has been shown to provide a precise, reliable and robust measurement of AMH levels.<a href=\"#note8\"><span class=\"s3\"><sup>8<\/sup><\/span><\/a><\/span><span class=\"s2\"><sup>,<\/sup><a href=\"#note9\"><span class=\"s3\"><sup>9<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note17\"><span class=\"s3\"><sup>17<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note18\"><span class=\"s3\"><sup>18<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note19\"><span class=\"s3\"><sup>19<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note20\"><span class=\"s3\"><sup>20<\/sup><\/span><\/a><\/span><span class=\"s1\">\u00a0This fully automated Elecsys<\/span><span class=\"s2\"><sup>\u00ae<\/sup><\/span><span class=\"s1\">\u00a0AMH Plus immunoassay, run on the\u00a0<b>cobas<\/b><\/span><span class=\"s2\"><sup>\u00ae<\/sup><\/span><span class=\"s1\">\u00a0<b>e<\/b>\u00a0and Elecsys<\/span><span class=\"s2\"><sup>\u00ae<\/sup><\/span><span class=\"s1\">\u00a0immunoassay analysers, determines AMH levels in 18 minutes, making it appropriate for routine clinical use. The Elecsys<\/span><span class=\"s2\"><sup>\u00ae<\/sup><\/span><span class=\"s1\">\u00a0AMH Plus immunoassay is intended to be used for assessment of ovarian reserve, prediction of response to COS and establishment of the individual daily dose of Rekovelle in combination with body weight in COS for the development of multiple follicles in women undergoing an assisted reproductive technology programme.<a href=\"#note8\"><span class=\"s3\"><sup>8<\/sup><\/span><\/a><\/span><span class=\"s2\"><sup>,<\/sup><a href=\"#note9\"><span class=\"s3\"><sup>9<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note17\"><span class=\"s3\"><sup>17<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note18\"><span class=\"s3\"><sup>18<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note19\"><span class=\"s3\"><sup>19<\/sup><\/span><\/a><sup>,<\/sup><a href=\"#note20\"><span class=\"s3\"><sup>20<\/sup><\/span><\/a><\/span><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">For more information, please contact<\/h3>\n<p><strong>Lindsey Rodger<\/strong><br \/>\n<em>Corporate Communications Manager<\/em><br \/>\n+41 58 451 40 23 (direct)<br \/>\n+41 79 191 0486 (mobile)<br \/>\n<a href=\"mailto:lindsey.rodger@ferring.com\">lindsey.rodger@ferring.com<\/a><\/p>\n<p><strong>Bhavin Vaid<\/strong><br \/>\n<em>Head of Corporate Communications<\/em><br \/>\n+41 58 301 09 52 (direct)<br \/>\n+41 79 191 06 32 (mobile)<br \/>\n<a href=\"mailto:bhavin.vaid@ferring.com\">bhavin.vaid@ferring.com<\/a><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">References<\/h3>\n<ol>\n<li id=\"note1\">Havelock J, Bosch E, Sanchez F, et al. Cumulative ongoing pregnancy and live birth rates following repeated controlled ovarian stimulation (COS) cycles using individualised follitropin delta dosing compared to conventional follitropin alfa dosing [abstract] In: 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2017; Geneva, Switzerland. Abstract no. 0-168<\/li>\n<li id=\"note2\">La Marca A, Nelson S, Gothberg M, et al. The impact of serum anti-M\u00fcllerian hormone (AMH) levels on clinical outcome of individualized follitropin delta dosing and conventional follitropin alfa dosing in controlled ovarian stimulation [abstract]. In: 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2017; Geneva, Switzerland.\u00a0 Abstract no. 0-174<\/li>\n<li id=\"note3\">Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualised versus conventional ovarian stimulation for an in vitro fertilization: a multicenter, randomized, controlled assessor-blinded, phase 3 noninferiority trial.\u00a0<em>Fertil Steril.<\/em>\u00a02017: 107(2): 387-396<\/li>\n<li id=\"note4\">Buur Rasmussen A et al. Low immunogenicity potential of follitropin delta, a recombinant FSH preparation produced from a human cell line: Results from phase 3 trials (ESTHER-1 and ESTHER-2).\u00a0<em>Human Reproduction<\/em>\u00a02016; 31: 385<\/li>\n<li id=\"note5\">Rekovelle<sup>\u00ae<\/sup>\u00a0Summary of Product Characteristics (SmPC) \u2013 Available at:\u00a0<a href=\"https:\/\/www.medicines.org.uk\/emc\/medicine\/33324\">https:\/\/www.medicines.org.uk\/emc\/medicine\/33324<\/a>\u00a0[Last accessed: June 2017]<\/li>\n<li id=\"note6\">Arce JC, Andersen AN, Fern\u00e1ndez-S\u00e1nchez M, et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone\u2013stratified, dose\u2013response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection.\u00a0<em>Fertil Steril.<\/em>\u00a02014;102(6):1633\u20131640<\/li>\n<li id=\"note7\">Olsson H, Sandstr\u00f6m R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line.\u00a0<em>J Clin Pharmacol.<\/em>\u00a02014; 54(11):1299\u20131307<\/li>\n<li id=\"note8\">Deeks ED. Elecsys<sup>\u00ae<\/sup>\u00a0AMH assay: a review in anti-M\u00fcllerian hormone quantification and assessment of ovarian reserve.\u00a0<em>Mol Diagn Ther.<\/em>\u00a02015; 19: 245-249<\/li>\n<li id=\"note9\">Roche Diagnostics. Elecsys<sup>\u00ae<\/sup>\u00a0AMH (anti-Mullerian hormone): Method sheet. 2015. https:\/\/pim-eservices.roche.com. [Last accessed June 2017]<\/li>\n<li id=\"note10\">La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).\u00a0<em>Hum Reprod Update. 2010;<\/em>\u00a016(2):113-130<\/li>\n<li id=\"note11\">OHSS Symptoms and Causes. Patient Care and Health Information. Mayo Clinic.\u00a0<a href=\"http:\/\/www.mayoclinic.org\/diseases-conditions\/ovarian-hyperstimulation-syndrome-ohss\/symptoms-causes\/dxc-20263586\">http:\/\/www.mayoclinic.org\/diseases-conditions\/ovarian-hyperstimulation-syndrome-ohss\/symptoms-causes\/dxc-20263586<\/a>\u00a0[Last accessed: June 2017]<\/li>\n<li id=\"note12\">Salmassi A, Mettler L, et al.Cut-Off Levels of Anti-Mullerian Hormone for the Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome.\u00a0<em>Int J Fertil Steril<\/em>. 2015; 9(2): 157-167<\/li>\n<li id=\"note13\">Delvigne A, Rozenberg S, et al. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.\u00a0<em>Hum Reprod Update.<\/em>\u00a02002; 8(6): 559-577<\/li>\n<li id=\"note14\">Thomsen L, Humaidan P, et al. Ovarian hyperstimulation syndrome in the 21<sup>st<\/sup>\u00a0century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin.\u00a0<em>Curr Opin Obstet Gynecol.<\/em>\u00a02015; 27(3): 210-214<\/li>\n<li id=\"note15\">Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.\u00a0<em>Hum Reprod.<\/em>\u00a02011; 26(9): 2353-2362<\/li>\n<li id=\"note16\">Fertility Treatment in 2014 Trends and Figures Report. Human Fertilisation and Embryology Authority.\u00a0<a href=\"http:\/\/www.hfea.gov.uk\/docs\/HFEA_Fertility_treatment_Trends_and_figures_2014.pdf\">http:\/\/www.hfea.gov.uk\/docs\/HFEA_Fertility_treatment_Trends_and_figures_2014.pdf<\/a>\u00a0[Last accessed June 2017]<\/li>\n<li id=\"note17\">Gassner D, Jung R. First fully automated immunoassay for anti-M\u00fcllerian hormone.\u00a0<em>Clin Chem Lab Med<\/em>. 2014;52(8):1143-1152<\/li>\n<li id=\"note18\">Anderson RA, Anckaert E, Bosch E, et al. Prospective study into the value of the automated Elecsys antim\u00fcllerian hormone assay for the assessment of the ovarian growing follicle pool.\u00a0<em>Fertil Steril<\/em>. 2015;103(4):1074\u201380.e4<\/li>\n<li id=\"note19\">Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent antim\u00fcllerian hormone assays.\u00a0<em>Fertil Steril.<\/em>\u00a02015;104(4):1016-1021.e6<\/li>\n<li id=\"note20\">Hyldgaard J, Bor P, Ingerslev HJ, et al. Comparison of two different methods for measuring anti-mullerian hormone in a clinical series.\u00a0<em>Reprod Biol Endocrinol.<\/em>\u00a02015;13(1):107<\/li>\n<\/ol>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_row element_name=&#8221;Row&#8221; wrap_type=&#8221;content-width&#8221; parallax_image_height=&#8221;content-height&#8221; parallax_image_movement=&#8221;fixed&#8221; parallax_image_speed=&#8221;0.5&#8243; bg_video_loop=&#8221;yes&#8221; parallax_video_height=&#8221;window-height&#8221; parallax_video_overlay=&#8221;none&#8221; row_overlay_opacity=&#8221;0&#8243; row_col_pos=&#8221;default&#8221; minimize_row=&#8221;no&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_button button_text=&#8221;READ MORE PRESS RELEASES&#8221; button_size=&#8221;standard&#8221; button_colour=&#8221;accent&#8221; button_type=&#8221;standard&#8221; rounded=&#8221;no&#8221; button_dropshadow=&#8221;no&#8221; button_link=&#8221;\/media\/press-releases\/&#8221; button_target=&#8221;_self&#8221; align=&#8221;center&#8221; animation=&#8221;none&#8221; animation_delay=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [\/spb_row]\n","protected":false},"excerpt":{"rendered":"<p>[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] New analysis of Rekovelle\u00ae data presented at ESHRE showed similar cumulative live birth rates compared to conventional therapy New analysis of Rekovelle data also [&hellip;]<\/p>\n","protected":false},"author":2410,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[244],"tags":[],"class_list":["post-22821","post","type-post","status-publish","format-standard","hentry","category-press-release-2017"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.3 (Yoast SEO v23.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients - Ferring Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients\" \/>\n<meta property=\"og:description\" content=\"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] New analysis of Rekovelle\u00ae data presented at ESHRE showed similar cumulative live birth rates compared to conventional therapy New analysis of Rekovelle data also [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Ferring Global\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-04T10:23:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-10T17:08:09+00:00\" \/>\n<meta name=\"author\" content=\"pulse\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ferring\" \/>\n<meta name=\"twitter:site\" content=\"@ferring\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"pulse\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/\"},\"author\":{\"name\":\"pulse\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\"},\"headline\":\"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients\",\"datePublished\":\"2017-07-04T10:23:53+00:00\",\"dateModified\":\"2021-05-10T17:08:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/\"},\"wordCount\":1881,\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"articleSection\":[\"PRESS RELEASE 2017\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/\",\"url\":\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/\",\"name\":\"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients - Ferring Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/#website\"},\"datePublished\":\"2017-07-04T10:23:53+00:00\",\"dateModified\":\"2021-05-10T17:08:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ferring.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ferring.com\/#website\",\"url\":\"https:\/\/www.ferring.com\/\",\"name\":\"Ferring Pharmaceuticals\",\"description\":\"Helping people live better lives\",\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ferring.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ferring.com\/#organization\",\"name\":\"Ferring\",\"url\":\"https:\/\/www.ferring.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"contentUrl\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"width\":236,\"height\":154,\"caption\":\"Ferring\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\",\"https:\/\/x.com\/ferring\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\",\"name\":\"pulse\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"caption\":\"pulse\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients - Ferring Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/","og_locale":"en_US","og_type":"article","og_title":"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients","og_description":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] New analysis of Rekovelle\u00ae data presented at ESHRE showed similar cumulative live birth rates compared to conventional therapy New analysis of Rekovelle data also [&hellip;]","og_url":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/","og_site_name":"Ferring Global","article_publisher":"https:\/\/www.facebook.com\/ferringpharmaceuticals\/","article_published_time":"2017-07-04T10:23:53+00:00","article_modified_time":"2021-05-10T17:08:09+00:00","author":"pulse","twitter_card":"summary_large_image","twitter_creator":"@ferring","twitter_site":"@ferring","twitter_misc":{"Written by":"pulse","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/#article","isPartOf":{"@id":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/"},"author":{"name":"pulse","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d"},"headline":"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients","datePublished":"2017-07-04T10:23:53+00:00","dateModified":"2021-05-10T17:08:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/"},"wordCount":1881,"publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"articleSection":["PRESS RELEASE 2017"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/","url":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/","name":"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients - Ferring Global","isPartOf":{"@id":"https:\/\/www.ferring.com\/#website"},"datePublished":"2017-07-04T10:23:53+00:00","dateModified":"2021-05-10T17:08:09+00:00","breadcrumb":{"@id":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ferring.com\/ferring-announces-new-analysis-of-rekovelle-data-relating-to-personalised-medicine-in-fertility-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ferring.com\/"},{"@type":"ListItem","position":2,"name":"Ferring announces new analysis of Rekovelle\u00ae data relating to personalised medicine in fertility patients"}]},{"@type":"WebSite","@id":"https:\/\/www.ferring.com\/#website","url":"https:\/\/www.ferring.com\/","name":"Ferring Pharmaceuticals","description":"Helping people live better lives","publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ferring.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ferring.com\/#organization","name":"Ferring","url":"https:\/\/www.ferring.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/","url":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","contentUrl":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","width":236,"height":154,"caption":"Ferring"},"image":{"@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ferringpharmaceuticals\/","https:\/\/x.com\/ferring"]},{"@type":"Person","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d","name":"pulse","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","caption":"pulse"}}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22821"}],"collection":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/users\/2410"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/comments?post=22821"}],"version-history":[{"count":0,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22821\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/media?parent=22821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/categories?post=22821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/tags?post=22821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}